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HIV-1 evades host defense through mutations and recombination events, generating
numerous variants in an infected patient. These variants with an undiminished virulence
can multiply rapidly in order to progress to AIDS. One of the targets to intervene in
HIV-1 replication is the trans-activator of transcription (Tat), a major regulatory protein
that transactivates the long terminal repeat promoter through its interaction with trans-
activation response (TAR) RNA. In this study, HIV-1 infected patients (n = 120) from
North India revealed Ser46Phe (20%) and Ser61Arg (2%) mutations in the Tat variants
with a strong interaction toward TAR leading to enhanced transactivation activities.
Molecular dynamics simulation data verified that the variants with this mutation had
a higher binding affinity for TAR than both the wild-type Tat and other variants that
lacked Ser46Phe and Ser61Arg. Other mutations in Tat conferred varying affinities for
TAR interaction leading to differential transactivation abilities. This is the first report from
North India with a clinical validation of CD4 counts to demonstrate the influence of Tat
genetic variations affecting the stability of Tat and its interaction with TAR. This study
highlights the co-evolution pattern of Tat and predominant nucleotides for Tat activity,
facilitating the identification of genetic determinants for the attenuation of viral gene
expression.
Keywords: HIV-1 Tat, transactivation, TAR RNA, genetic variations, recombination, mutations
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) overcomes the host immune defense by
rapid evolution and genetic diversification (Dougherty and Temin, 1988; Jetzt et al., 2000).
Rapid replication without the benefit of proof-reading leads to the generation of a large
number of mutations and recombination events (Wolinsky et al., 1996; Jetzt et al., 2000). This
vigorous recombination allows HIV-1 to produce multiple groups, subtypes, sub-subtypes and
recombinants in an infected patient (Wolinsky et al., 1996; Buonaguro et al., 2007). Of these,
only highly virulent variants and recombinants are likely to adapt and spread in a population
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(Ho et al., 1995; Buonaguro et al., 2007). It is known that genetic
and functional changes in HIV-1 genes accomplished with an
emergence of recombination events (Blackard et al., 2002), could
affect the virulence of HIV-1 resulting in vulnerability to AIDS
despite antiretroviral therapy (ART) (Geretti, 2006; Kirchhoff,
2009; Sharp and Hahn, 2011; Santoro and Perno, 2013).
Among HIV-1 proteins, trans-activator of transcription (Tat)
plays an important role in mediating the viral transcription
(Okamoto et al., 1996; Zhu et al., 1997). Tat is expressed
during the early stages of infection, which is encoded by two
exons (exons 1 and 2) in a multiple spliced mRNA (Arya
et al., 1985). Tat strongly activates transcription (Muesing et al.,
1987) from long terminal repeat (LTR) promoter through a
strong interaction with trans-activation response element (TAR)
sequence at the 5′ end of the LTR (+1 to +59) (Dingwall et al.,
1989; Buonaguro et al., 1994). During the binding to TAR and
host factors Cdk9 and cyclin T1, Tat alters the transcription
complex, recruiting a positive transcription elongation complex
(P-TEFb), an elongation factor composed of cyclin T1 (CycT1)
and Cdk9 that phosphorylates the C-terminal domain of RNA
polymerase II leading to the increased production of viral RNA
(Zhou and Rana, 2002). Tat contributes to the pathogenesis of
HIV-1 through its pivotal role in replication, T-cell apoptosis, co-
receptor regulation, cytokine induction, and other viral activities
in the host cells (Fulcher and Jans, 2003; Romani et al., 2010).
HIV-1 produces highly divergent variants within a single
patient, thereby overcoming the host immune responses,
antiretroviral restriction factors, and other selection mechanisms
(Konings et al., 2006; Coffin and Swanstrom, 2013). In India,
the dominant HIV-1 type is subtype C (>95%), with the
emergence of recombinants like A/C, A/E, and B/C (<2%)
(Neogi et al., 2011; Ronsard et al., 2015), indicating that HIV-1
is under the stress toward the positive selection in the Indian
population. Therefore, it is important to understand the nature
of HIV-1 evolution in the population. Previous data showed
that the genetic variations in Tat could lead to varying levels of
LTR-driven transcription (Ronsard et al., 2014); however, how
Tat variants differ in their transactivation abilities have not been
explored. Tat is also known for its interaction with various cellular
proteins and for its effect on modulating the viral gene expression,
which in turn enhances the virulence (Bucci, 2015; Mediouni
et al., 2015; Yuan et al., 2015) indicating one of the suitable
targets against HIV-1 infection (Hamy et al., 2000; Burton et al.,
2004; Nunnari et al., 2008; Sun et al., 2012; Ensoli et al., 2014).
We earlier reported that Tat is a highly conserved protein with
only a few genetic variations in the functional domains. However,
a novel Ser46Phe mutation is prevalent among North Indian
population (Ronsard et al., 2014). More than 20% of HIV-1
infected patients carry this mutation along with other mutations;
therefore it is important to understand the role of these variants
from the population.
Here, we report the differential ability of Tat variants with
Ser46Phe mutation to significantly enhanced LTR transactivation
(P < 0.05) compared to wild-type and other Tat variants that
lack this mutation. We observed that variants with this mutation
exhibited a strong interaction with TAR by in vitro and in silico
studies, whereas other Tat variants exhibited varying levels of
Tat–TAR mediated transactivation. Molecular dynamics (MDs)
simulation data confirmed that Ser46Phe mutation exhibits a
strong binding with TAR. Here, we illustrate how HIV-1 virus has
evolved during selection pressure in the North Indian population
with various mutations to adapt and survive in the host cells by
enhancing its functional activity.
RESULTS
Selection of Tat Variants for Functional
Characterization
HIV-1 specimens from 120 patients were collected, and the Tat
gene was amplified by polymerase chain reaction (PCR) and
sequenced as described in Section “Materials and Methods.”
From 120 variants, 15 variants were chosen based on mutations
in the Tat gene and these variants were segregated into three
groups (selected at least 3 variants in each group from total
120 variants which consisted of similar nucleotide changes) for
LTR transactivation study (Figure 1A). Next, three Tat variants
(TatN12, TatD60, and TatVT6) were selected based on their
similarity in inducing LTR transactivation and carrying similar
mutations (similar pattern of nucleotide changes) in the Tat
gene (selected a variant from each group as a representative
variant) for the TAR RNA interaction study which included
TatN12, a subtype C variant (that lacked Ser46Phe) with
Leu35Pro and Gly44Ser; TatD60, also a subtype C variant
(with Ser46Phe) with Glu9Lys and Ser61Arg; and TatVT6, a
B/C recombinant (that lacked Ser46Phe) (Figure 1B). Three
groups were chosen based on the similarities in their genetic
and functional activities of Tat (variants with similar nucleotide
changes resulting in similar levels of LTR transactivation). It
is worth mentioning that Ser46Phe mutation is also reported
from neighboring countries like Myanmar and China (HIV
database)1; however, the functional implication of this mutation
on Tat–TAR mediated transactivation has not been studied.
The phylogenetic tree was constructed with Tat variants to
explain the Tat genetic variations occurring in the North
Indian population (Supplementary Figure S1). Notably, the
three variants (TatD60, TatE59, and TatE64 were used for
transactivation study) and other variants (TatVT1, TatVT3,
TatA7, TatN14, TatN17, TatCSW1, TatS5, TatS6) with Ser46Phe
were clustered together in the phylogenetic tree indicating the
proper classification of Tat variants into three different groups
for the functional characterization. Further, the recombination
event was confirmed in the Tat variants (TatVT6) using
RIP (Recombinant Identification Program) with a confidence
threshold 90% and a window size of 100 (Supplementary
Figure S2).
Role of Tat Mutations on Viral
Transcription
To determine the transactivation activity of Tat variants, a
luciferase assay was performed in HEK293 cells with 15 selected
1http://www.hiv.lanl.gov/
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FIGURE 1 | HIV-1 LTR transactivation by Tat variants. (A) Tat variants from HIV-1 infected individuals (n = 15) were aligned with wild-type Tat C
(C.IN.93.93IN905). (B) Representative data of Tat variants[TatN12 (lack Ser46Phe) with Leu35Pro and Gly44Ser, TatVT6 (lack Ser46Phe) with B/C recombination and
TatD60 (with Ser46Phe)] were aligned with wild-type Tat C. (C) HEK293 cells were co-transfected with pCMV-myc Tat variants and pGL3-Luc subtype C LTR. After
24 h of transfection, cells were harvested and lysed and luciferase activity was measured. The relative transactivation was expressed as mean luciferase units.
Wild-type TatC was used as a reference Tat for comparison. Empty myc vector was used as a control. Subtype C LTR was used as a loading control. Luciferase
activity of 15 Tat variants and wild-type Tat C normalized to empty pCMV-myc vector. (D) Luciferase activity of unique Tat variants and wild-type TatC normalized to
empty pCMV-myc vector. Expression of Tat variants in HEK293 cells. HEK293 cells were transfected with pCMV-myc Tat variants and wild-type TatC. After 24 h,
cells were harvested and immunoblotted with anti-myc antibody. The relative Tat protein expression was measured using ImageJ software. Wild-type TatC was used
as a reference Tat for comparison. Empty myc vector was used as a control. GAPDH was used as a loading control. (E) Relative protein expression of Tat variants
and wild-type TatC. (F) Quantification of Tat protein expression normalized to GAPDH. Error bar represents the standard deviation in triplicates. Statistical
comparison of each Tat variant to Tat C was calculated by one-way ANOVA with the Tukey’s test (∗ denotes P < 0.05 and NS denotes not significant).
Tat variants of three groups. Wild-type TatC was used as a
reference for baseline transactivation levels of Tat variants.
Tat variants with similar nucleotide changes from all three
groups (n = 15) showed similar levels of LTR transactivation
suggesting that Tat-induced transactivation is dependent on
the genetic determinants of Tat variants (Figure 1C). We
observed that the levels of transactivation induced by TatN12
were similar or slightly lower than the wild-type TatC but
not significantly; TatVT6-induced LTR transactivation was a
slightly higher than wild-type TatC (P < 0.05). TatD60 carrying
Ser46Phe showed a significantly higher level of transactivation
(P < 0.05) than wild-type Tat C as well as other variants.
In summary, the order of transactivation induced by variants
TatD60 > TatV6 > TatN12 (Figure 1D) indicating Ser46Phe
mutation play a significant role in transactivation, whereas,
other natural mutations did not have a significant role on
LTR transactivation. Similar pattern of transactivation was
observed with the Tat variants along with the subtype B LTR
(Supplementary Figure S3).
Tat Mutations Affect Tat Protein
Expression
To examine the effect of Tat variants on intracellular protein
expression, Tat variants (TatN12, TatVT6, and TatD60) and
wild-type Tat C were cloned into a pCMV-myc vector and
were expressed and detected by immunoblotting with anti-myc
antibody. Wild-type Tat C was used as a reference for comparison
of protein expression. TatN12 and TatVT6 were expressed at
similar levels of protein expression when compared to wild-
type Tat C; while TatD60 (Ser46Phe) resulted in an elevated
level of expression (Figures 1E,F) suggesting that Ser46Phe
and Ser61Arg mutations in TatD60 could affect Tat protein
expression.
Tat Mutations Alter TAR Interaction
To examine the ability of Tat variants to interact with TAR,
Tat variants were over-expressed and purified from Escherichia
coli BL21 strain (Supplementary Figure S4). These proteins
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FIGURE 2 | Tat–TAR interaction by EMSA. Tat variants and wild-type Tat cloned in pGEX-4T2 vector were expressed in BL21 (DE3) pLysS cells. Expressed Tat
proteins were isolated and verified by immunoblotting with anti-Tat antibody. Increasing concentrations of purified Tat proteins were subjected to interact with
subtype B TAR and these Tat ± TAR complexes were detected by autoradiography. The relative intensity of Tat variants–TAR complexes were measured using
ImageJ software. Wild-type TatC–TAR complex was used as a reference Tat for comparison. GST was used as a control. Free TAR was used as a loading control.
(A) Relative intensity of Tat variants–TAR complexes and wild-type TatC–TAR complex. (B) Quantification of Tat variants–TAR complexes normalized to empty vector.
Error bar represents the standard deviation in triplicates. Statistical comparison of each Tat variant to Tat C was calculated by one-way ANOVA with the Tukey’s test
(∗ denotes P < 0.05 and NS denotes not significant).
were incubated with TAR (synthesized by in vitro transcription)
and Tat–TAR binding affinity was measured by Non-denaturing
PAGE. Wild-type TatC–TAR complex formation was used as a
reference. The binding affinity of TatN12 to TAR was less than
wild-type TatC–TAR complex but not significantly; whereas the
TatD60 variant carrying Ser46Phe showed significantly higher
(P < 0.05) binding affinity with TAR RNA (Figures 2A,B). The
binding affinity of the TatVT6–TAR complex was slightly higher
than wild-type TatC–TAR complex but did not reach statistical
significance.
Tat Genetic Variations Determine the
Protein Stability
To determine whether Ser46Phe and other mutations play a
role on Tat protein stability, a cycloheximide chase assay was
performed. Briefly, HEK293 cells were transfected with Tat
variants and incubated with cycloheximide for different time
intervals, and the amount of Tat in cell lysates was quantified by
western blotting. Wild-type Tat C protein stability was treated
as baseline. After 3 h of cycloheximide treatment, the level of
TatN12 was found to be reduced. In contrast, the protein levels of
TatD60 and TatVT6 were detectable even after 3 h of treatment
(Figures 3A,B) indicating that Ser46Phe and recombination
events in TatD60 and TatVT6 respectively could possibly stabilize
Tat protein.
Influence of Genetic Variability on Tat
Ubiquitination
To understand whether ubiquitination determines the
differential stability of Tat proteins, we measured the level
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FIGURE 3 | Intracellular stability of Tat variants. HEK293 cells were transfected with pCMV-Myc Tat variants and wild-type TatC, cycloheximide (100 µg/ml) was
added after 24 h and cells were harvested at different time intervals and immunoblotted with anti-Tat antibody. The relative percentage of Tat protein degradation was
measured using ImageJ software. Wild-type TatC was used as a reference Tat for comparison. Tat proteins expressed after 24 h of transfection (before adding
cycloheximide) were used as controls. GAPDH was used as a loading control. (A) Relative protein expression of Tat variants and wild-type TatC at different time
intervals. (B) Quantification of Tat protein degradation normalized to GAPDH. Error bar represents the standard deviation in triplicates. Statistical comparison of each
Tat variant to Tat C was calculated by one-way ANOVA with the Tukey’s test (∗ denotes P < 0.05 and NS denotes not significant).
FIGURE 4 | Ubiquitination of Tat variants. HEK293 cells were co-transfected with His6-Ubiquitin protein, and pCMV-myc Tat variants and wild-type TatC. After
24 h, cells were treated with MG132 (25 µM) for 8 h. Cell lysates were incubated with Ni-NTA beads and immunoblotted with anti-myc antibody. The relative intensity
of Tat protein ubiquitination was measured using ImageJ software. Wild-type TatC was used as a reference Tat for comparison. Empty vector was used as a control.
(A) Relative intensity of Tat proteins and wild-type Tat protein ubiquitination. (B) Quantification of Tat ubiquitination normalized to empty myc vector. Error bar
represents the standard deviation in triplicates. Statistical comparison of each Tat variant to Tat C was calculated by one-way ANOVA with the Tukey’s test (∗ denotes
P < 0.05 and NS denotes not significant).
of ubiquitination of Tat variants in HEK293 cells. Wild-type
Tat C ubiquitination was treated as baseline. TatN12 resulted
in slightly higher or similar level of ubiquitination compared
to wild-type Tat indicating less stability of this protein than
TatD60 and TatVT6 proteins. TatVT6 showed a slightly lower
ubiquitination than wild-type TatC while TatD60 showed less
ubiquitination indicating that Ser46Phe and Ser61Arg could
stabilize Tat protein (Figures 4A,B), though it is not known
if Ser46 and Ser61 are targets for ubiquitination (Wang et al.,
2007). The differential levels of ubiquitination of Tat variants
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appear to be dependent on the intracellular level of Tat protein
expression.
Tat Mutations Govern Stable Interaction
with TAR
Next, we performed MD simulation to estimate the stability
of TatD60–TAR and TatC–TAR complexes. We have made
homology models of wild-type Tat and TatD60, and then docked
with TAR RNA. TatC–TAR complex was treated as a baseline
stability of the complex. MD simulation recorded the trajectories
of Tat protein backbones and TAR in the docked complex for
20 nanoseconds (ns) in an aqueous environment. Root mean
square deviation (RMSD) of Tat protein backbone and TAR
ribonucleotides at t = 0 ns and t = 20 ns were compared to
predict the stability of the complexes.
Root mean square deviation of TatD60 backbone was observed
at around 5 Å and remained stable throughout the simulation,
except for a brief period of higher shift between 8 and 10 ns
(Figure 5A). In contrast, RMSD for TatC backbone showed more
fluctuations. In particular, the upward movement observed after
8 ns was not completely stabilized at the end of the simulation.
The average length of protein backbone RMSD for the final
5 ns of simulation, 5.2 Å for TatD60 and 5.7 Å for wild-type
TatC, indicated that TatD60–TAR complex had higher stability
at equilibrium than wild-type TatC–TAR complex.
Root mean square deviation of TAR ribonucleotides in
TatD60–TAR complex showed more drift when compared to
TatC–TAR complex (Figure 5B), particularly from 8 to 10 ns.
The comparison of extracted TAR structure alone at different
time frames showed that RMSD was reduced by 19.3 Å in
TatD60–TAR complex and by 7.8 Å in wild-type TatC–TAR
complex. This reduction could be due to Ser46Phe mutation in
TatD60 which created a conformational change in order to bind
strongly with TAR ribonucleotides and produced a more stable
TatD60–TAR complex.
Next, root mean square fluctuation (RMSF) of each amino
acid in Tat proteins differed between TatD60 and TatC. For TatC,
maximum fluctuations were observed for five residues at Ser31,
Tyr32, His33, Lys41, and Gly42 in addition to the N-terminal
and the C-terminal residues (Figure 5C). For TatD60, maximum
fluctuations were observed for only three residues at Gly15, Ser16,
and Lys19 in addition to the N-terminal residues (Figure 5C).
RMSF was lower for Ser70 and Lys71 in TatD60 when compared
to wild-type TatC.
In the case of TAR, ribonucleotides in the bulge region
(U23, C24, and U25) involved in Tat interaction, have similar
RMSF when interacting with TatC or TatD60, however the loop
ribonucleotide G32 appeared to be more flexible in TatC–TAR
complex (Figure 5D). RMSF of each TAR ribonucleotides in
TatD60–TAR complex showed less drift when compared to
TatC–TAR complex (Figure 5D).
Hydrogen Bonds in Tat–TAR Complexes
In wild-type TatC, Ser46 resulted in a single H-bond with
TAR (occupancy ∼71%) (Figure 5E), while the corresponding
position was Phe46 in TatD60 resulting in one H-bond with
TAR only transiently (occupancy below 1%); evidently, the single
Ser46Phe mutation had a considerable effect on the H-bond
profile of the TatD60–TAR complex (Figure 5F). In case of
ribonucleotides in TAR, the wild-type Tat had less interaction
(Figure 5G) than compared to TatD60 (Figure 5H) indicating
strong H-interaction of TatD60 toward TAR.
Further, analysis of simulated structures at 20 ns revealed
potentially critical differences in Tat–TAR interaction at bulge
ribonucleotides A22, U23, C24, and U25. TatD60–TAR complex
showed stacking interaction between U23 and A22, and standard
base-pairing between coplanar bases A22 and U40 (Figure 5I)
whereas both these features were missing in the TatC–TAR
complex (Figure 5J). Overall, the number of hydrogen bonds
formed between Tat variants and TAR represented in the order
of TatD60> TatVT6> TatN12.
Binding Free Energy and its Residue
Wise Decomposition Analysis of Tat–TAR
Interaction
To understand the changes in free energy during formation
of Tat variants–TAR, complexes were computed using residue-
wise energy decomposition analysis by MM/GBSA method.
TatC–TAR was used as a reference for Tat–TAR complex free
energy decomposition. 1Gbind of TatD60–TAR was estimated
to be −80.49 kcal/mol, whereas in TatC–TAR 1Gbind was
−67.14 kcal/mol (Supplementary Table S1). The main forces
contributing to the difference between 1Gbind for TatD60–TAR
and TatC–TAR were van der Waals and electrostatic interactions.
Residue-wise binding energy decomposition (Figure 5K and
Supplementary Table S2) showed significant contributions by
the following residues in TatD60: Leu35 (−6.447 ± 9.452),
Arg49 (−12.070 ± 15.687), Lys51 (−5.266 ± 18.739), Arg53
(−13.688 ± 12.174), Gln54 (−8.058 ± 9.557), and Asn67
(−8.708 ± 6.229), and the following residues in TatC:
Arg49 (−16.524 ± 17.477), Lys51 (−7.876 ± 14.652), Arg52
(−10.619 ± 16.843), and Arg53 (−6.192 ± 24.679). In contrast,
both TatC and TatD60, Gln54 (0.065 ± 7.828) and Asn67
(0.181 ± 7.948) disfavored the binding ability. These findings
further support evidence for a higher affinity of TatD60 for TAR.
Comparison of Crystal Structure and
Modeled Structure of Tat–TAR Complex
Further, we have analyzed the Tat crystal structure (PDB ID:
5L1Z) with TAR RNA (Figure 5L) and then the complex was
compared to the Tat homology modeled complex with TAR
RNA (Figure 5M). In spite of having few differences in the
Tat modeled protein and in the Tat crystal structure, their
binding pattern with TAR RNA were found to be similar
and also both the complexes were following the same trend
in making the hydrogen bonds. The residues Lys50, Lys 51,
Arg52, Arg55, Ser57, Asn67, and Ser70 are the major residues
contributing more toward the Tat and TAR binding were
the same in corresponding residues in the crystal structure
(PDB ID: 5L1Z). The additional hydrogen bonds formed in
the crystal structure were Thr40 and Tyr46. Those additional
hydrogen bonds with hydrogen bond distance 2.5 and 2.8 Å
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FIGURE 5 | Molecular dynamic (MD) simulation of Tat protein with TAR. MD simulation for Tat–TAR was carried out for 20 ns to predict root mean square
deviation (RMSD) of Tat variants. (A) RMSD of Tat residues in wild-type TatC–TAR (Red line) and TatD60–TAR (Blue line). (B) RMSD of TAR ribonucleotides in
wild-type TatC–TAR (Red line) and TatD60–TAR (Blue line). (C) Root mean square fluctuation (RMSF) of Tat individual residues in wild-type TatC–TAR (red line) and
TatD60–TAR (blue line). (D) RMSF of TAR individual ribonucleotides in wild-type TatC–TAR (red line) and TatD60–TAR (blue line). Hydrogen bonds in Tat–TAR
complex. Number of H-bonds formed between Tat variants and TAR per time frame was measured; (E) number of H-bonds in wild-type TatC–TAR complex (red line)
and TatD60–TAR complex (blue line). (F) Number of H-bonds formed at Ser46th position in wild-type TatC–TAR complex (red line) and at Phe46 in TatD60–TAR
complex (blue line). (G) Number of H-bonds formed by TAR ribonucleotides of A22 (black line), U23 (red line), C24 (green line), and U25 (blue line) in wild-type
TatC–TAR complex. (H) Number of H-bonds formed by TAR ribonucleotides of A22 (black line), U23 (red line), C24 (green line) and U25 (blue line) in TatD60–TAR
complex. Tat variants interaction with TAR during simulation. Tat protein (blue) and TAR (green) interaction in the bulge region at the end of 20 ns simulation was
captured. H-bonds represented in dotted blue lines. (I) Structure of wild-type TatC–TAR complex during 20 ns simulation. (J) Structure of TatD60–TAR complex
during 20 ns simulation. Binding free energy of Tat–TAR complex. (K) Relative residue-wise energy contribution for binding wild-type TatC–TAR and TatD60–TAR
complexes. Only selected residues with important contribution are shown. Comparison of crystal structure and modeled structure of Tat–TAR complex. Comparison
of docked structure of Tat–TAR complex with homology modeled Tat structure and with the crystal structure (PDB ID: 5L1Z) of Tat. (L) Crystal structure complex of
TatD60–TAR. (M) Homology modeled structure complex of TatD60–TAR.
were distinct from the Tat modeled structure as it was modeled
as extended loop and it was away from the C19 and U22
respectively.
Clinical Status of HIV-1 Infected Patients
with Tat Variants
In this study, CD4 counts were follow-up for 6 months for HIV-1
infected patients (n= 15) which included: group 1 was consisted
of HIV-1 infected patients (n = 9) lacking Ser46Phe in Tat C;
group 2 was consisted of HIV-1 infected patients (n = 3) lacking
Ser46Phe in Tat B/C recombinant; and group 3 was consisted of
HIV-1 infected patients (n = 3) with Ser46Phe and Ser61Arg in
Tat C.
Of these 15 patients, the mean CD4 count in group 1 patients
(n = 9) was 470, and after 6 months of ART, the mean value
of CD4 count increased to 557 with ±87 standard deviation
of the mean value. This showed that the patients in group 1
benefited from ART and indicated that there was no effect of
Tat mutations on CD4 counts. However, two patients (TatE4 and
TatD58) had almost constant CD4 counts while the other seven
patients had increased CD4 counts. Next, the mean CD4 count
in group 2 patients (n = 3) was 613, and after 6 months of
ART, the mean value of CD4 count decreased to 578 with ±35
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standard deviation of the mean value. This showed that the CD4
counts of the patients in group 2 could be affected by B/C Tat;
however, the changes were not significant. In group 3 patients
(n= 3), the mean CD4 count was 493. After 6 months of ART, the
mean value of CD4 count decreased to 359 with ±134 standard
deviation of the mean value. This showed that the patients in this
mutation group 3 could be affected due to Ser46Phe and other
mutations in this group (Supplementary Table S3).
In the total of 15 patients, the mean viral load after ART in
group 1 patients (n= 9) was less than 50 copies/ml. This showed
that the patients did not affected by the transactivation level
induced by Tat mutations in this group (particularly TatN12 is
<50 copies/ml). However, two patients (TatE4 and TatD61) had
slightly detectable viral loads but not significantly. Next, the mean
viral load in group 2 patients (n= 3) was slightly increased to 158
copies/ml. This showed that the viral load of the patients could
be affected by the transactivation level induced by B/C Tat in this
group (particularly TatVT6 is 182 copies/ml). In group 3 patients
(n = 3), the mean viral loads was 265 copies/ml indicating that
the patients in this mutation group 3 could be affected by the
transactivation level caused due to Ser46Phe and other mutations
in this group (particularly TatD60 is 346 copies/ml), however,
there could be also multiple other factors might affect both the
CD4 count and the viral load indicating the need for the further
study in a large sample size (Supplementary Table S3).
DISCUSSION
A rate-limiting factor in the management of HIV infections, is
the plethora of genetic variations leading to failure of clinical
trials (Santoro and Perno, 2013). Each geographical region
has its own profile of HIV-1 types, subtypes, recombinants
and mutations, and these genetic variations lead to differential
potential in inducing HIV-1 pathogenesis (Rodriguez et al.,
2009). We previously reported the differential expression of
certain viral genes of subtypes B and C with respect to their
functions (Sood et al., 2008; Gupta and Banerjea, 2009). The
viral or cellular components responsible for these differences have
not been studied in details and in most cases, the molecular
details of these genetic determinants have not been well-explored.
Our previous reports showed that the functional role of viral
proteins is mediated by the genetic determinants present in the
viral genes (Siu et al., 2013; Zhu et al., 2013). It is known that Tat
subtype-specific variations exhibit widely differing viral activities
including their ability to activate the HIV-1 LTR promoter (Li
et al., 2012); however, the functional and clinical consequences
of the substantial genetic variations of Tat occurring in North
India have not been studied. The growing number of studies on
Tat-based inhibitors against HIV-1 replication (Hamy et al., 1997;
Lalonde et al., 2011) indicates the importance of this study.
In this regard, we attempted to understand the differential
ability of Tat variants to activate LTR transactivation through
their ability to interact with TAR using in vitro and in silica
approaches. Tat protein is highly conserved protein among North
Indians. For viral replication, it is important that Tat retains its
functional activity because any changes in the genetic makeup
of Tat could lead to drastic modulation in transcription-coupled
pathogenicity. In our survey of 120 Tat sequences from 120
HIV-1 infected patients, we found certain point mutants and
B/C recombinants commonly occurring among North Indians.
In order to understand the role of these natural mutations, we
carried out genetic and functional analyses in correlation with
clinical CD4 counts. Both in silico and in vitro studies show that
the Ser46Phe mutation in Tat results in enhanced transactivation.
Next, to demonstrate how Ser46Phe contributed toward high
transactivation activity. Wild-type TatC (that lacked Ser46Phe)
was used as a reference Tat to compare their differential abilities
to interact with TAR and their intracellular protein stability. We
also used two other subtype C variants, TatN12 and TatVT6 (that
lacked Ser46Phe) found in the studied population. These variants
showed less transactivation than TatD60 (with Ser46Phe).
Tat transactivates HIV-1 LTR by binding to TAR, which is
a critical step in the process of transcription (Huq et al., 1997;
Rana and Jeang, 1999). Residues vital for Tat function include
Lys28, Lys41, Lys50, Lys51, and Lys71 (for acetylation); Arg57
and Arg56 (for TAR interaction); and Tyr47, Cys22, Cys31,
and Cys34 (for LTR transactivation) (Huo et al., 2011). Most
of these residues were highly conserved among North Indians;
however, we found that variants with Ser46Phe showed higher
transactivation of LTR than TatC indicating the importance
of this mutation. We studied 15 Tat variants for their ability
to induce transactivation and found that variants with similar
mutations resulted in similar levels of transactivation indicating
the vital role of genetic variations in modulating functions.
From 15 variants, we selected three variants namely TatN12
(Leu35Pro; Gly44Ser), TatD60 (Ser46Phe), and TatVT6 (B/C
recombinant) as representative variants to understand the role
of genetic determinants on transactivation, TAR interaction and
stability. TatVT6 showed increased transactivation, which may
be due to subtype C specific changes in the N-terminus and
subtype B specific changes in the C-terminus. TatN12 showed
less transactivation (not significant) than wild-type TatC which
could possibly be due to unique mutations in TatN12 leading to
weak interaction with TAR. However, the biological and clinical
relevance of the reported Tat mutations remains to be established
with reference to TAR sequence variations from patients.
MD simulation is a useful technique to determine the stability
of biological complexes (Hornak et al., 2006; Deng et al.,
2011; Johnson et al., 2012; Venken et al., 2012; Zhao et al.,
2013; Vijayan et al., 2014), here, we utilized this technique
to calculate the fluctuations and the binding free energy of
Tat–TAR complex (Nifosi et al., 2000). Data generated from
MD simulation substantiate our in vitro studies and provide
further insights into a stronger interaction of TatD60 with
TAR. The TatD60–TAR complex was more stable during the
simulation with a stronger interaction between Tat and TAR.
As predicted in the electrophoretic mobility shift assay (EMSA)
experiment, the interaction between TatD60 (with Ser46Phe)
and TAR were different in the simulation experiment. This
difference has led to additional H-bond interactions between the
residues namely Tyr26, Tyr29, Cys30, Ser31, Tyr47, and Ser70 in
TatD60 to TAR interaction, whereas wild-type TatC lacks these
residue interactions toward TAR. In case of TAR, ribonucleotide
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U23 and A22 led to additional H-bonds interaction with
TatD60, resulting in strong TAR interactions. Further, binding
free energy calculation and residue-wise energy decomposition
analyses clearly suggested that TatD60–TAR complex interacted
more stably when compared to wild-type TatC–TAR complex.
Particularly, the residues Gln54 and Asn67 in TatD60, but not in
TatC, contributed to the binding.
TatD60 appeared to have a more stable half-life than other
TatC variants within the host cells, possibly due to lower level
of ubiquitination, it is clear from the fact that it has enhanced
transactivation. Given its enhanced potency for transactivation
and its higher stability in the cells, TatD60 has the potential to
be more virulent than other TatC variants studied here. This
hypothesis was supported by our observation of CD4 counts in
the patients that were the source of these variants (Supplementary
Table S3). However, these predictions need to be tested in
a large sample population. Correlating Tat variants, especially
variants with Ser46Phe, with the course of the disease, as well as
response to ART, would provide molecular and clinical insights
to managing HIV-1 patients in North India.
There could be other factors involved in the decline of CD4
counts in HIV-1 infected patients, however, we believe that this
study with the control groups (that lacked Ser46Phe) showcase
the genetic variations of Tat that could be one of the reasons
for the decline. At present, it was difficult to draw a conclusion
on CD4 counts and viral loads with the small sample size and
warrant further need for monitoring the genetic evolution of
HIV-1 strains among North Indians.
Future studies to evaluate the binding efficiency of Tat
variants during complex with P-TEFb (Schulze-Gahmen et al.,
2014) should further support this relationship. Taken together,
this study illustrates the importance of point mutations for
modulating the specific functional activities of Tat, which include
increasing transactivation levels. These variants have the ability to
emerge as a virulent HIV-1 strains in North India. Retrospective
studies on Tat–TAR complex show that inhibition of this complex
is an attractive target for developing novel antiviral drugs (Yang,
2005; Mousseau et al., 2015) and Tat could be also used as a
vaccine candidate (Ensoli et al., 2016); therefore, manipulation
of Tat–TAR interaction by silencing important residues is critical
in forming the Tat–TAR complex as this would provide a
strategy for suppressing viral gene expression. Continued studies
are needed to elucidate how Tat variants manipulate the host
immune cells in this population. Further, our results suggest that
the nucleotides of Tat and their functions should be routinely
investigated as a correlation of transactivation levels. Thus,
this study provides valuable insights into the evolving events
underlying the ability of the virus to adapt and enhance its
replication by generating mutations and recombination events.
MATERIALS AND METHODS
Ethics Statement and Collection of
Samples
This study design was approved by Research Project Advisory
Committee, Institutional Biosafety Committee, and Institutional
Ethical Committee for Human Research of University College
of Medical Sciences (UCMS) and Guru Teg Bahadur (GTB)
Hospital, Delhi, India, and from Post Graduate Institute
of Medical Education and Research (PGIMER), Chandigarh,
India. These institutes are mentored by the National AIDS
Control Organization (NACO), Ministry of Health and Family
Welfare, Government of India that provides free ART to HIV-1
seropositive patients under a structured HIV/AIDS Control
Program. Written informed consent was obtained from HIV-1
infected adult patients (n = 105) and from the guardians of
HIV-1 infected children participants (n = 15) in this study.
Blood samples were collected from HIV-1 infected patients
(n= 120; males= 68, females= 52) registered and monitored at
immunodeficiency clinics in GTB Hospital and PGIMER during
the period from 2004 to 2010.
Estimation of CD4 Counts and Viral
Loads
HIV-1 infects CD4+ T cells and reduces these cells to a
minimum level which is an indicator for the early risk of
acquired immunodeficiency syndrome (AIDS) than viral load.
People living with HIV AIDS (PLHA) patients under ART have
shown improved CD4 counts and longer life span. ART was
started in HIV-1 infected patients having CD4 count below
350/ml and children with varying counts. In this view, our study
was undertaken to evaluate the correlation between Tat genetic
variations on CD4 counts after 6 months on ART. From ART
patients, blood was collected (CD4 counts were measured at this
stage) and Tat gene was amplified, after 6 months on ART, once
again CD4 counts and viral loads were measured and analyzed
statistically. The CD4 count was estimated by flow cytometry
using manufacturer’s directions (BD Biosciences) and viral load
was measured using Real Time PCR (Taqman). The viral load
of less than 50 copies/ml was defined as a viral suppression or
undetectable viral load.
DNA Isolation and Polymerase Chain
Reaction (PCR)
Genomic DNA was extracted from PBMCs of HIV-1 infected
patients by QIAamp DNA Blood Mini Kit (Qiagen) and HIV-1
subtype C (Indian isolate 93IN905 GenBank accession number
AF067158 obtained from AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) were used for
amplification by PCR using the following primers:
Forward primer: 5′-ATGGAGCCAGTAGATCCTAACCTA-3′
Reverse primer: 5′-TTGCTTTGATATAAGATTTTGATGA
TCCT-3′
PCR was carried out in a 15 µl reaction volume. The reaction
mixture contained 500 ng genomic DNA (2 µl), 10× PCR
Buffer (1.5 µl), 10 mM dNTP mix (0.37 µl), 1 µL of each
primer (25 pmol), 0.25 µl of Takara Taq DNA polymerase and
8.88 µl of DNase/RNase free water. PCR conditions for the
above primer sets were as follow: initial denaturation at 94◦C
for 5 min (1 cycle), 30 cycles of denaturation at 94◦C for 15 s,
annealing at 63◦C for 30 s and extension at 72◦C for 40 s, and
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a final extension at 72◦C for 5 min (1 cycle). PCR amplified
products were analyzed on 1.5% agarose gel. Tat amplified from
Indian HIV-1 subtype C (C.IN.93.93IN905) was used as wild-type
TatC for comparison study with Tat variants. The Tat sequences
were amplified both from the PBMCs viral DNA and also from
the plasma viral RNA to find the exact genetic variations. The
nucleotide sequences of Tat from both the source were similar in
the pattern.
Cloning, Sequencing, and HIV-1
Sub-typing
The gel purified PCR products were cloned into pGEM-T easy
vector (Promega). The ligation reaction was incubated at 4◦C
for 10 h then the ligation mix was added to LB ampicillin plates
with E. coli DH5α strain. The plates were incubated overnight at
37◦C. The positive clones were selected by picking a single colony
and grown in 5 ml LB Broth with ampicillin (100 µg/ml) and
incubated overnight at 37◦C. Plasmid DNA was isolated from the
culture by QIAprep Spin Mini Kit (Qiagen). The positive clones
were screened by restriction digestion of plasmid DNA with
EcoRI in a 10 µl reaction volume at 37◦C for 2 h. The digested
products were analyzed on a 1.5% agarose gel. The positive clones
were commercially sequenced from LabIndia and SciGenom
laboratories. The nucleotide sequences were assembled and error
was checked by using BLAST to search for sequence similarities to
previously reported sequences in the databases and to eliminate
potential laboratory errors. HIV-1 sub-typing, recombination,
phylogenetic tree and mutational analyses have been carried out
as described (Ronsard et al., 2014, 2015).
Plasmids and Antibodies
TatC (lack Ser46Phe) and Tat variants (TatN12, TatD60, TatVT6)
were cloned into: (a) mammalian expression vector pCMV-myc
vector (Clonetech) under the CMV promoter for functional
studies, and (b) prokaryotic expression vector pGEX-4T-2
(Invitrogen) to obtain GST-tagged proteins. HIV-1 subtype B
TAR was cloned in pcDNA3.1 (Invitrogen) for TAR synthesis
to determine Tat–TAR binding activity. Anti-Tat antibody (NIH
AIDS Reagent Programme), Anti-myc antibody (Clontech),
Anti-GAPDH antibody (Cell Signaling Technology), Anti-rabbit
IgG conjugated to HRP (Jackson Immunoresearch), and Anti-
Mouse IgG conjugated to HRP (Jackson Immunoresearch) were
used in western blotting.
Cell Culture and Transfection
Human embryonic kidney (HEK) 293 cells (NIH AIDS
Reagent Programme) were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Himedia Laboratories) supplemented
with L-glutamine and sodium pyruvate, fetal calf serum
(10%), penicillin (100 U/ml), streptomycin (0.1 mg/ml), and
amphotericin B (0.25 µg/ml) at 37◦C in the presence of 5% CO2.
Cells were transfected with lipofectamine 2000 (Invitrogen) in
serum free DMEM media.
Western Blotting
HEK293 cells were transfected with 1 µg of pCMV-myc Tat
variants (TatN12, TatVT6, and TatD60) and wild-type TatC.
After 24 h, cells were harvested and total protein was extracted
using RIPA lysis buffer (Invitrogen). The amount of protein
was estimated by BCA Assay (Pierce). Tat proteins were run on
12% SDS-PAGE and transferred to the nitrocellulose membrane
(BIORAD) using standard methods (Chaudhuri et al., 2015;
Mohankumar et al., 2015; Sridharan et al., 2015). The membrane
was incubated with anti-myc antibody followed by Anti-rabbit
IgG conjugated to HRP. The membrane was developed using
ECL reagent (Amersham). GAPDH was used as a loading
control and the expression of proteins was normalized with
the amount of GAPDH. 1 µg of the empty pCMV-myc
vector was used as a control in all the experiments and the
experiment was repeated three times for confirmation of the
result.
Luciferase Reporter Assay
HEK293 cells were co-transfected with 200 ng of pCMV-myc Tat
variants and wild-type TatC in each well of 6 well plate along
with 50 ng of pGL3-Luc vector containing subtype C LTR. Cells
were transfected only with subtype C. LTR construct was used
as a control. After 24 h of transfection, cells were harvested and
lysed with reporter lysis buffer (Promega) and luciferase activity
was measured in the luminometer. 200 ng of the empty pCMV-
myc vector was used as a control and the luciferase activity was
normalized to the empty vector; the experiment was performed
in triplicate.
Purification of Tat Proteins
Tat variants and wild-type Tat were cloned into pGEX-4T-2
vector. E. coli BL21 (DE3) PlysS cells were transformed
with recombinant plasmids and grown at 37◦C overnight.
Recombinant protein expression was induced by IPTG for
3 h at 37◦C. Cells were harvested, disrupted and recombinant
proteins were purified using Glutathione-agarose (Pierce) using
manufacturer’s directions.
Electrophoretic Mobility Shift Assay
(EMSA)
Subtype B TAR was cloned between HindIII and BamHI
site in pCDNA3 vector (Promega). 32P-labeled TAR was
transcribed in vitro using T7 RNA polymerase. TAR was
incubated with increasing amounts of purified Tat protein
(0.1–2 µg) for 10 min on ice, followed by 10 min at
37◦C with binding buffer (Promega). The reaction was
stopped by adding 4X gel loading buffer and Tat variants
with TAR complexes were analyzed on 4% Non-denaturing
polyacrylamide gels and autoradiography was done. 1 µg of
the empty pCMV-myc empty vector was used as a control
and the expression of Tat–TAR binding was normalized with
interaction with empty vector; the experiment was repeated three
times.
Cycloheximide Chase Assay
HEK293 cells were transfected with 1 µg of pCMV-myc
Tat variants. After 24 h, cycloheximide was added (final
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concentration 100 µg/mL). Cells were harvested at different
time intervals (0, 1, 2, and 3 h). Cell lysates were made
with 1X RIPA lysis buffer and resolved by 12% SDS-PAGE.
Anti-Tat antibody was used for detection by immunoblotting.
GAPDH was used as a loading control and the expression
of proteins was normalized with the amount of GAPDH. Tat
proteins expressed after 24 h of transfection (before adding
cycloheximide) were used as controls; the experiment was
repeated three times.
In Vitro Ubiquitination Assay
HEK293 cells were co-transfected with 1 µg of pCMV-myc
Tat variants and 1 µg of His6-Ubiquitin Protein for 24 h and
processed as previously described (Verma et al., 2011). The
expression of proteins was normalized with the amount of empty
vector. 1 µg of the empty pCMV-myc vector was used as a
control; the experiment was repeated three times.
Homology Models and MD Simulations
Homology models of Tat protein variants were generated using
the solution structure of Tat protein as a template (PDB ID:
1TAC) and a crystal structure (PDB ID: 5L1Z) using Modeller
9v8 (Eswar et al., 2007) and then docked using HADDOCK
web server (Guru Interface) (Eisenberg et al., 1997). Models
were validated using PROCHECK (Laskowski et al., 1996)
and the 3D-1D score of Verify3D (Bowie et al., 1991; Luthy
et al., 1992). MD simulations were performed using GROMACS
v4.5.6 (Van Der Spoel et al., 2005; Pronk et al., 2013) with
AMBER99SB-ILDN force field (Lindorff-Larsen et al., 2010).
Tat–TAR complex was solvated in a cubic box using TIP3P
water model. The solvated systems were subjected to energy
minimization using steepest descent and conjugate gradient
algorithms keeping energy gradient convergence cut off of
10 kJ mol−1 nm−1. LINCS algorithm was used to calculate
all the covalent bonds with hydrogen. The time step was kept
at 2 femtoseconds (fs) for the simulation. The cut-off distance
of 10 Å was used for all short-range non-bonded interactions
and 12 Å Fourier grid spacing in PME was used for long-
range electrostatics. NVT and NPT steps were run for 250
picoseconds (ps) and the final production run was done for 20
nanoseconds (ns).
Binding Free Energy Calculations
The binding free energy of Tat–TAR complex was estimated
by using MM/GBSA python scripts implemented in Amber11
package (Kollman et al., 2000; Campanera and Pouplana,
2010). Energy calculations were done over 5000 frames of 5
ns trajectory. Residue-wise energy decomposition studies were
performed over the same trajectory using Amber decomposition
script, which highlights important interactions between Tat
proteins and TAR, and to identify the crucial residues in Tat
proteins.
Statistical Analysis
Data were analyzed using the SPSS 7.5-Windows student version
software (SPSS, Inc., Chicago, IL, USA). One-way ANOVA
followed by Tukey’s test was used to assess statistical significance
between groups (P < 0.05 represents significance and P < 0.01
represents high significance) (Mohankumar et al., 2014a,b).
Accession Numbers
Sequences of 120 Tat variants are available at – (GenBank:
FJ432068-FJ432079, FJ210870-FJ210875, EU583126-EU583128,
EU551665, FJ429357, FJ429358, HQ110624-HQ110630,
HQ110608-HQ110623, JQ918787-JQ918788, GU451679-
GU451681, and HQ011384-HQ011385). Sequences of unique
Tat variants are available at (GenBank: TatN12 – HQ110625,
TatVT6 – FJ432073, TatD60 – HQ110614).
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